Re-evaluation of the risk for major adverse cardiovascular events in patients treated with anti-IL-12/23 biological agents for chronic plaque psoriasis: a meta-analysis of randomized controlled trials.

Tzellos, T; Kyrgidis, A; Zouboulis, C C

Tzellos, T; Kyrgidis, A; Zouboulis, C C.

Affiliation

Tzellos T; Department of Dermatology, Dessau Medical Center, Dessau, Germany.

J Eur Acad Dermatol Venereol ; 27(5): 622-7, 2013 May.

Article in En | MEDLINE | ID: mdl-22404103

Subject(s)

Antibodies/therapeutic use; Cardiovascular Diseases/chemically induced; Interleukin-12/immunology; Interleukin-23/immunology; Psoriasis/drug therapy; Randomized Controlled Trials as Topic; Antibodies/adverse effects; Antibodies/immunology; Chronic Disease; Double-Blind Method; Humans; Placebos

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Psoriasis / Cardiovascular Diseases / Randomized Controlled Trials as Topic / Interleukin-12 / Interleukin-23 / Antibodies Type of study: Clinical_trials / Etiology_studies / Risk_factors_studies / Systematic_reviews Limits: Humans Language: En Journal: J Eur Acad Dermatol Venereol Journal subject: DERMATOLOGIA / DOENCAS SEXUALMENTE TRANSMISSIVEIS Year: 2013 Document type: Article Affiliation country: Germany

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google